Abstract library

51 results for "Cuesta Hernandez".
#864 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Medullary Thyroid Cancer: A Retrospective Cohort Study
Introduction: Hereditary Medullary Thyroid Cancer (MTC) accounts for 20-30% of cases and has some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#865 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Pheochromocytoma and Paraganglioma: A Retrospective Cohort Study
Introduction: Hereditary Pheochromocytomas (PCC) and Paragangliomas (PGL) account for 30-35% of cases and have some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#2992 The PanNENomics Project: A Call for an International Collaborative Effort Built on the Success of the LungNENomics Project
Introduction: Neuroendocrine tumors are rare understudied diseases at the molecular level, especially those occurring in sites outside the lung and the gastrointestinal track. This lack of knowledge has strong implications for the clinical management of these diseases (Rindi et al. Mad Pathol 2018).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: PhD Lynnette Fernandez-Cuesta
#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study
Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
#3006 Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma
Introduction: Mature cystic teratoma (MCT) is the most common type of germ cell tumor in the ovary. A malignant tumor that arises in a pre-existing mature teratoma is called teratoma with malignant transformation (TMT).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia
#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report
Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Rocío Morales Herrero
#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Matthieu Foll
#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD INES DE TORRES